{"id":"cannabidiol-400","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Drowsiness"},{"rate":"5-15%","effect":"Diarrhea"},{"rate":"5-15%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Cannabidiol 400 binds to cannabinoid receptors in the body, influencing various physiological processes, including pain perception, inflammation, and mood regulation. This interaction can lead to therapeutic benefits in conditions such as epilepsy and multiple sclerosis. However, the exact mechanisms underlying cannabidiol's effects are still being researched and understood.","oneSentence":"Cannabidiol 400 acts as a cannabinoid receptor agonist, modulating the endocannabinoid system to exert therapeutic effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:48:35.872Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seizure disorders"},{"name":"Multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT05942911","phase":"PHASE2","title":"Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Incannex Healthcare Ltd","startDate":"2023-11-22","conditions":"Rheumatoid Arthritis","enrollment":20},{"nctId":"NCT04587791","phase":"EARLY_PHASE1","title":"Cannabidiol in Opioid Use Disorder and Chronic Pain","status":"RECRUITING","sponsor":"Yale University","startDate":"2021-12-08","conditions":"Chronic Pain, Opioid Use Disorder","enrollment":34},{"nctId":"NCT04550377","phase":"PHASE2","title":"Cannabidiol as a Treatment for PTSD and PTSD Comorbid With TBI","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2021-05-26","conditions":"Post Traumatic Stress Disorder, Traumatic Brain Injury","enrollment":120},{"nctId":"NCT07148206","phase":"PHASE3","title":"Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial","status":"NOT_YET_RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2026-05","conditions":"Opioid Use Disorder","enrollment":40},{"nctId":"NCT07278505","phase":"PHASE1, PHASE2","title":"Study of Cannabidiol and Neuroimaging on Stress","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2025-10-28","conditions":"Early Life Adversity, Trauma, Stress","enrollment":160},{"nctId":"NCT06940674","phase":"PHASE3","title":"Adjunctive Cannabidiol for Recovery From Opioid Study","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2025-06-13","conditions":"Opioid Use Disorder (OUD)","enrollment":450},{"nctId":"NCT05023070","phase":"PHASE1","title":"Investigation of the Pharmacokinetic Profile of CBD - Phase 1 ANANDA","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2021-07-22","conditions":"Healthy","enrollment":24},{"nctId":"NCT07001930","phase":"PHASE1","title":"Effects of Cannabidiol on Stress and Nicotine Withdrawal","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-08-25","conditions":"CBD, Stress, Nicotine Dependence","enrollment":90},{"nctId":"NCT06930703","phase":"PHASE1, PHASE2","title":"Cannabidiol in Sickle Cell Disease","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2025-04-03","conditions":"Sickle Cell Disease","enrollment":52},{"nctId":"NCT06575751","phase":"PHASE2","title":"Cannabidiol and Cannabis Concentrate Users","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2024-12-04","conditions":"Cannabis Use Disorder","enrollment":120},{"nctId":"NCT06569394","phase":"PHASE2","title":"A Study of Cannabidiol in Young Adult Cannabis Users","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2024-12-09","conditions":"Cannabis Use Disorder","enrollment":200},{"nctId":"NCT06218056","phase":"PHASE2","title":"Cannabidiol for Reducing Cigarette Use","status":"RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2024-10-31","conditions":"Tobacco Use Disorder, Tobacco Smoking, Tobacco Dependence","enrollment":120},{"nctId":"NCT06578455","phase":"PHASE1","title":"A Pharmacokinetic Study to Compare CBD-NE to Epidyolex in Healthy Adult Volunteers Under Both Fed and Fasted Conditions","status":"COMPLETED","sponsor":"dsm-firmenich Switzerland AG","startDate":"2024-08-30","conditions":"CBD Pharmacokinetics, Healthy Participants","enrollment":32},{"nctId":"NCT06629389","phase":"PHASE2","title":"Clinical Trial with Cannabidiol (Kanbis®) for Parkinson Disease Symptoms","status":"RECRUITING","sponsor":"Laboratorio Elea Phoenix S.A.","startDate":"2024-11-28","conditions":"Parkinson Disease","enrollment":88},{"nctId":"NCT06514066","phase":"PHASE2, PHASE3","title":"Cannabidiol's Role in Dementia Management","status":"NOT_YET_RECRUITING","sponsor":"Hospital Pengajar Universiti Putra Malaysia","startDate":"2024-09-01","conditions":"Dementia, Vascular, Dementia, Mixed","enrollment":486},{"nctId":"NCT04911127","phase":"PHASE1","title":"Therapeutic Response of Cannabidiol in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2021-10-05","conditions":"Rheumatoid Arthritis, Cannabis","enrollment":67},{"nctId":"NCT04396730","phase":"PHASE4","title":"Cannabidiol and Oral Contraceptive Pills: Exploring a Drug-Drug Interaction","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2020-04-08","conditions":"Contraception","enrollment":9},{"nctId":"NCT02539823","phase":"PHASE2","title":"Acute and Short-term Effects of CBD on Cue-induced Craving in Drug-abstinent Heroin-dependent Humans","status":"COMPLETED","sponsor":"Hurd,Yasmin, Ph.D.","startDate":"2015-09","conditions":"Opiate Addiction","enrollment":45},{"nctId":"NCT02751359","phase":"PHASE1, PHASE2","title":"Characterization of the Analgesic Effect of CBD in Healthy, Normal Volunteers","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2016-07","conditions":"Pain","enrollment":18},{"nctId":"NCT02559167","phase":"PHASE2","title":"Cannabidiol and Cocaine Craving/Dependence","status":"COMPLETED","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2016-07-01","conditions":"Substance Use Disorder, Cocaine Dependence, Withdrawal From Addictive Substance; Detoxification","enrollment":79},{"nctId":"NCT01605539","phase":"PHASE2","title":"Acute and Short-term Effects of Cannabidiol Admin on Cue-induced Craving in Drug-abstinent Heroin Dependent Humans","status":"COMPLETED","sponsor":"Hurd,Yasmin, Ph.D.","startDate":"2012-05","conditions":"Opiate Addiction","enrollment":10},{"nctId":"NCT04205682","phase":"EARLY_PHASE1","title":"Cannabidiol (CBD) for the Treatment of Alcohol Withdrawal","status":"UNKNOWN","sponsor":"South West Sydney Local Health District","startDate":"2020-01","conditions":"Alcohol Withdrawal, Alcohol Dependence","enrollment":52},{"nctId":"NCT01844687","phase":"PHASE2","title":"Laboratory Study of Cannabidiol on the Effects of Smoked Marijuana","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2013-05","conditions":"Smoking, Marijuana","enrollment":50},{"nctId":"NCT01284634","phase":"PHASE2","title":"Study to Evaluate the Effect of GWP42003 on Liver Fat Levels in Participants With Fatty Liver Disease","status":"COMPLETED","sponsor":"GW Research Ltd","startDate":"2011-05-03","conditions":"Fatty Liver","enrollment":25},{"nctId":"NCT03607643","phase":"PHASE1, PHASE2","title":"A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies","status":"UNKNOWN","sponsor":"Leaf Vertical Inc.","startDate":"2019-01-15","conditions":"Cancer of Pancreas, Cancer of Liver, Cancer of Rectum","enrollment":160},{"nctId":"NCT02478424","phase":"PHASE2","title":"Extended Use of Cannabidiol for the Prevention of Graft-versus-host-disease","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2015-07","conditions":"Graft vs Host Disease","enrollment":10},{"nctId":"NCT02392780","phase":"PHASE2","title":"Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host Disease","status":"UNKNOWN","sponsor":"moshe yeshurun","startDate":"2015-04","conditions":"Acute-graft-versus-host Disease","enrollment":10},{"nctId":"NCT01311778","phase":"PHASE1","title":"Study to Test the Safety and Efficacy of Cannabidiol as a Treatment Intervention for Opioid Relapse","status":"COMPLETED","sponsor":"Hurd,Yasmin, Ph.D.","startDate":"2010-02","conditions":"Opiate Addiction","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CBD"],"phase":"phase_2","status":"active","brandName":"Cannabidiol 400","genericName":"Cannabidiol 400","companyName":"Hurd,Yasmin, Ph.D.","companyId":"hurd-yasmin-ph-d","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cannabidiol 400 acts as a cannabinoid receptor agonist, modulating the endocannabinoid system to exert therapeutic effects. Used for Seizure disorders, Multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}